Cargando…

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers

Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine kinase 1, 2 and 3 (NTRK1, NTRK2 and NTRK3) genes, respectively. TRKs can regulate cell proliferation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Tingting, Wang, Guan, Liu, Yao, Feng, Lu, Wang, Meng, Liu, Jie, Chen, Yi, Ouyang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893124/ https://www.ncbi.nlm.nih.gov/pubmed/33643817 http://dx.doi.org/10.1016/j.apsb.2020.05.004

Ejemplares similares

Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
por: Jiang, Tingting, et al.
Publicado: (2022)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
por: Wong, Derek, et al.
Publicado: (2019)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101
por: Nagasubramanian, Ramamoorthy, et al.
Publicado: (2016)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII
por: Farina, Antonietta Rosella, et al.
Publicado: (2018)

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
por: Schirrmacher, Ralf, et al.
Publicado: (2019)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
por: Demetri, G. D., et al.
Publicado: (2020)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021)

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
por: Cappellesso, Rocco, et al.
Publicado: (2022)

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours
por: Li, Yuehua, et al.
Publicado: (2022)

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
por: Hsiao, Susan J., et al.
Publicado: (2019)

A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma
por: Wang, Xiang, et al.
Publicado: (2019)

Somatic rearrangement of the tropomyosin-receptor-kinase (trk) oncogene is rare in gastrointestinal cancer.
por: Fey, M. F., et al.
Publicado: (1988)

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
por: Klink, Andrew J., et al.
Publicado: (2022)

Identification and characterization of the Cucurbitacins, a novel class of small-molecule inhibitors of Tropomyosin receptor kinase a
por: Zhong, Yueling, et al.
Publicado: (2019)

NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer()()
por: Choi, Yuri, et al.
Publicado: (2018)

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
por: O’Reilly, E M, et al.
Publicado: (2019)

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma
por: Wang, Hejing, et al.
Publicado: (2023)

EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
por: Goto, Hiroaki, et al.
Publicado: (2020)

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
por: Moccia, Marialuisa, et al.
Publicado: (2021)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
por: Konicek, Bruce W., et al.
Publicado: (2018)

TRK inhibitors in TRK fusion-positive cancers
por: Drilon, A
Publicado: (2019)

A small molecule inhibitor of tropomyosin dissociates actin binding from tropomyosin-directed regulation of actin dynamics
por: Bonello, Teresa T., et al.
Publicado: (2016)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
por: Perreault, Sébastien, et al.
Publicado: (2021)

TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis
por: Medford, Arielle J., et al.
Publicado: (2023)

Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis
por: Nwosu, Lilian N, et al.
Publicado: (2016)

Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer
por: Gomez, Daniel Richard, et al.
Publicado: (2018)

Fusion partners of NTRK3 affect subcellular localization of the fusion kinase and cytomorphology of melanocytes
por: de la Fouchardière, Arnaud, et al.
Publicado: (2020)

HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours
por: Nysom, Karsten, et al.
Publicado: (2022)

Small molecule activators of the Trk receptors for neuroprotection
por: Webster, Nicholas JG, et al.
Publicado: (2008)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023)

Sensory Neuron-Specific Deletion of Tropomyosin Receptor Kinase A (TrkA) in Mice Abolishes Osteoarthritis (OA) Pain via NGF/TrkA Intervention of Peripheral Sensitization
por: O-Sullivan, InSug, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l844e9hsn1v8ensc32ldbrslg6